Received Aug 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | OT |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | — | OT |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | OT |
No additional AE; HCP called and reported a patient who received a dose of inactivated polio vaccine (IPV) and a dose of PROQUAD on 24JUL2025. Patient also received two total doses of MMR-II in 2023. No additional information was provided. No additional AE/PQC.; HCP called and reported a patient who received a dose of inactivated polio vaccine (IPV) and a dose of PROQUAD on 24JUL2025. Patient also received two total doses of MMR-II in 2023. No additional information was provided. No additional AE/PQC.; This spontaneous report was received from a nurse and refers to a 7-year-old patient of unknown gender. The patient's medical history and concurrent conditions were not reported. Concomitant medications included Polio vaccine inactivated (IPV). On an unspecified dates in 2023, the patient received two total doses of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), administered by unknown route (lot # and expiration date were not reported) as prophylaxis (Inappropriate schedule of product administration). On 24-Jul-2025, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), 1 dosage form, administered by unknown route (lot # and expiration date were not reported) as prophylaxis (Extra dose administered). The suspect vaccines were reconstituted with sterile diluent (no details reported). No additional information was provided. No additional adverse events. At the reporting time, the outcome of the events was unknown. The action taken with the suspect products was not reported, but established as not applicable.
Inactivated polio vaccine (IPV); Sterile diluent